NFKB1 and neoplasm: HER2-low tumors harbored almost no ERBB2 amplification and expressed HER2 protein in the tumor cell membrane by several mechanisms, including estrogen receptor pathways, the NF-kB pathway activated by chemoradiotherapy and epigenetic changes [10].